Inspira Technologies OXY B.H.N. (NASDAQ:IINN) Shares Down 10.5% – Here’s Why

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) shares traded down 10.5% during trading on Thursday . The stock traded as low as $1.65 and last traded at $1.70. 6,659,308 shares traded hands during trading, an increase of 1,790% from the average daily volume of 352,435 shares. The stock had previously closed at $1.90.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Inspira Technologies OXY B.H.N. in a research note on Friday, April 10th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Inspira Technologies OXY B.H.N. Price Performance

The company has a fifty day moving average of $1.16 and a two-hundred day moving average of $0.87. The company has a quick ratio of 1.30, a current ratio of 1.56 and a debt-to-equity ratio of 0.08.

Institutional Trading of Inspira Technologies OXY B.H.N.

Institutional investors and hedge funds have recently modified their holdings of the company. Yorkville Advisors Global LP boosted its holdings in shares of Inspira Technologies OXY B.H.N. by 10.9% during the 1st quarter. Yorkville Advisors Global LP now owns 1,977,724 shares of the company’s stock worth $883,000 after buying an additional 193,880 shares during the period. Kestra Advisory Services LLC bought a new position in Inspira Technologies OXY B.H.N. in the 4th quarter worth $71,000. Finally, Citadel Advisors LLC bought a new position in Inspira Technologies OXY B.H.N. in the 3rd quarter worth $105,000. 12.72% of the stock is currently owned by institutional investors and hedge funds.

About Inspira Technologies OXY B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.